Why the study?
To present the perspective that muscle research is entering a fourth wave driven by interest in small molecules as research tools and potential therapies for muscle diseases.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Small-molecule modulators may expand options for cardiac and skeletal muscle diseases; leaves open prospective trials before clinical adoption.
The study of muscle and contractility is an unusual scientific endeavour since it has from the start been focussed on one problem-What makes muscle work?-and yet has needed a vast range of different approaches and techniques to study it. Its uniqueness lies in the fundamental fascination of a large scale molecular machine that converts chemical energy into mechanical energy at ambient temperature and with high efficiency that is also controlled by an exquisitely intricate yet utterly reliable regulatory system and is an essential component of animal life. The investigation of muscle is as innovative as any other field of research. As soon as one approach appears to be played out another comes along. It is instructive to consider this as a series of waves of novel and heightened activity starting in the 1950s. The thesis of this article is that we are approaching the fourth wave with the recent rise of interest in small molecules as research tools and possible therapies for muscle diseases.
No takes yet. Share an insight, caveat, or question.
Steven B. Marston (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: